Touro College of Osteopathic Medicine, Middletown, NY, USA.
Geisinger Commonwealth School of Medicine, Scranton, PA, USA.
Forensic Sci Int. 2023 Mar;344:111579. doi: 10.1016/j.forsciint.2023.111579. Epub 2023 Jan 31.
The US opioid overdose epidemic continues to escalate. The restrictions on methadone availability including take-home dosing were loosened during the COVID-19 pandemic although there have been concerns about the high street value of diverted methadone. This report examined how fatal overdoses involving methadone have changed over the past two-decades including during the pandemic.
The CDC's Wide-ranging Online Data for Epidemiologic Research (WONDER) was used to find the unintentional methadone related overdose death rate from 1999 to 2020. Unintentional methadone deaths were defined using the ICD X40-44 codes with only data for methadone (T40.3). Data from the DEA's Automation of Reports and Consolidated Orders System (ARCOS) on methadone overall use, opioid treatment programs use, and pain management use was gathered for all states for 2020 and corrected for population.
There have been dynamic changes over the past two-decades in methadone overdoses. Overdoses increased from 1999 (0.9/million) to 2007 (15.9) and declined until 2019 (6.5). Overdoses in 2020 (9.6) were 48.1% higher than in 2019 (t(50) = 3.05, p < .005). The state level correlations between overall methadone use (r(49) = +0.75, p < .001), and opioid treatment program use (r(49) = +0.77, p < .001) with overdoses were positive, strong, and statistically significant. However, methadone use for pain treatment was not associated with methadone overdoses (r(49) = -0.08).
Overdoses involving methadone significantly increased by 48.1% in 2020 relative to 2019. Policy changes that were implemented following the COVID-19 pandemic involving methadone take-homes may warrant further study before they are made permanent.
美国阿片类药物过量的流行情况仍在持续恶化。尽管存在对美沙酮(methadone)外流至高街的价值的担忧,但在新冠疫情期间,美沙酮的可携带回家剂量限制有所放宽。本报告研究了在过去二十年中,包括在疫情期间,涉及美沙酮的致命过量用药情况发生了哪些变化。
本研究使用美国疾病控制与预防中心(CDC)的广域在线数据用于流行病学研究(WONDER)数据库,查找 1999 年至 2020 年期间非故意美沙酮相关过量用药的死亡率。非故意美沙酮死亡定义采用 ICD X40-44 编码,仅包含美沙酮(T40.3)的数据。从 DEA 的自动化报告和综合订单系统(ARCOS)收集了全美 2020 年美沙酮总体使用情况、阿片类药物治疗计划使用情况和疼痛管理使用情况的数据,并根据人口进行了校正。
在过去的二十年中,美沙酮用药过量情况发生了动态变化。1999 年(0.9/百万)至 2007 年(15.9),用药过量增加,直到 2019 年(6.5),用药过量减少。2020 年(9.6)的用药过量比 2019 年(t(50) = 3.05,p <.005)高出 48.1%。美沙酮总体使用量(r(49) = +0.75,p <.001)和阿片类药物治疗计划使用量(r(49) = +0.77,p <.001)与用药过量之间的州级相关性呈正相关、强相关且具有统计学意义。然而,美沙酮用于疼痛治疗与美沙酮用药过量无关(r(49) = -0.08)。
与 2019 年相比,2020 年涉及美沙酮的用药过量增加了 48.1%。在新冠疫情之后,美沙酮可携带回家的政策变化可能需要进一步研究,然后再将其永久化。